DK1294378T3 - Trombopoietin-mimetika - Google Patents

Trombopoietin-mimetika

Info

Publication number
DK1294378T3
DK1294378T3 DK01941599T DK01941599T DK1294378T3 DK 1294378 T3 DK1294378 T3 DK 1294378T3 DK 01941599 T DK01941599 T DK 01941599T DK 01941599 T DK01941599 T DK 01941599T DK 1294378 T3 DK1294378 T3 DK 1294378T3
Authority
DK
Denmark
Prior art keywords
thrombopoietin mimetic
thrombopoietin
mimetic
Prior art date
Application number
DK01941599T
Other languages
English (en)
Inventor
Kevin J Duffy
Connie L Erickson-Miller
Daniel F Eppley
Julian Jenkins
Juan I Luengo
Nannan Liu
Alan T Price
Antony N Shaw
Sophie Visonneau
Kenneth Wiggall
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26901947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1294378(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of DK1294378T3 publication Critical patent/DK1294378T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • C07D231/48—Oxygen atom in position 3 or 5 and nitrogen atom in position 4 with hydrocarbon radicals attached to said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
DK01941599T 2000-05-25 2001-05-24 Trombopoietin-mimetika DK1294378T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20708400P 2000-05-25 2000-05-25
US22892900P 2000-08-30 2000-08-30
PCT/US2001/016863 WO2001089457A2 (en) 2000-05-25 2001-05-24 Thrombopoietin mimetics

Publications (1)

Publication Number Publication Date
DK1294378T3 true DK1294378T3 (da) 2008-01-28

Family

ID=26901947

Family Applications (3)

Application Number Title Priority Date Filing Date
DK07112105T DK1864981T3 (da) 2000-05-25 2001-05-24 Thrombopoietin-mimetiske stoffer
DK07112106.5T DK1889838T3 (da) 2000-05-25 2001-05-24 Thrombopoietin-mimetika
DK01941599T DK1294378T3 (da) 2000-05-25 2001-05-24 Trombopoietin-mimetika

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK07112105T DK1864981T3 (da) 2000-05-25 2001-05-24 Thrombopoietin-mimetiske stoffer
DK07112106.5T DK1889838T3 (da) 2000-05-25 2001-05-24 Thrombopoietin-mimetika

Country Status (30)

Country Link
US (9) US7160870B2 (da)
EP (3) EP1294378B1 (da)
JP (2) JP3813875B2 (da)
KR (2) KR100847172B1 (da)
CN (4) CN101343250B (da)
AR (2) AR030696A1 (da)
AT (2) ATE374772T1 (da)
AU (2) AU2001274938C1 (da)
BE (1) BE2010C018I2 (da)
BR (1) BRPI0111116B8 (da)
CA (1) CA2411468C (da)
CY (4) CY2010012I2 (da)
CZ (1) CZ303176B6 (da)
DE (4) DE60139354D1 (da)
DK (3) DK1864981T3 (da)
ES (3) ES2294000T3 (da)
FR (1) FR10C0034I2 (da)
HK (4) HK1055561A1 (da)
HU (3) HU230487B1 (da)
IL (5) IL152988A0 (da)
LU (1) LU91681I2 (da)
MX (1) MXPA02011621A (da)
MY (1) MY136707A (da)
NO (3) NO324246B1 (da)
NZ (2) NZ533308A (da)
PL (2) PL216528B1 (da)
PT (3) PT1889838E (da)
SI (3) SI1294378T1 (da)
TW (1) TWI305207B (da)
WO (1) WO2001089457A2 (da)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2002126616A (ru) 2000-03-08 2004-03-20 Метабэйсис Терапьютикс, Инк. (Us) Новые арильные ингибиторы фруктозо-1, 6-бисфосфатазы
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
US20110212054A1 (en) * 2000-05-25 2011-09-01 Glaxosmithkline Llc. Thrombopoietin mimetics
EP1370252A4 (en) * 2001-03-01 2006-04-05 Smithkline Beecham Corp Thrombopoietin mimetics
US7659409B2 (en) 2002-03-19 2010-02-09 Mitsubishi Chemical Corporation 3-Hydroxy-3-(2-thienyl) propionamides and production method thereof, and production method of 3-amino-1-(2-thienyl)-1-propanols using the same
TWI280128B (en) * 2002-05-22 2007-05-01 Smithkline Beecham Corp 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US7414040B2 (en) * 2002-06-06 2008-08-19 Smithkline Beecham Corporation Thrombopoietin mimetics
CA2495184A1 (en) 2002-08-14 2004-02-26 Nissan Chemical Industries, Ltd. Thrombopoietin receptor activators and process for their production
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
EP2387998A1 (en) 2003-04-29 2011-11-23 Glaxosmithkline LLC Methods for treating degenerative diseases/injuries
US20090298179A1 (en) * 2003-04-29 2009-12-03 Connie Erickson-Miller Methods For Treating Degenerative Diseases/Injuries
US20090143453A1 (en) * 2003-04-29 2009-06-04 Connie Erickson-Miller Methods for treating degenerative diseases/injuries
US20090048318A1 (en) * 2003-04-29 2009-02-19 Connie Erickson-Miller Methods for treating degenerative diseases/injuries
US20100004302A1 (en) * 2003-04-29 2010-01-07 Connie Erickson-Miller Methods for Treating Degenerative Diseases/Injuries
US7753958B2 (en) * 2003-08-05 2010-07-13 Gordon Charles R Expandable intervertebral implant
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
TW200526638A (en) * 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
AU2005286592A1 (en) * 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
MX2007004765A (es) 2004-10-25 2007-07-09 Ligand Pharm Inc Compuestos y metodos que modulan la actividad de la trombopoyetina.
RU2395505C2 (ru) 2004-12-08 2010-07-27 Ниссан Кемикал Индастриз, ЛТД 3-этилиденгидразино-замещенные гетероциклические соединения в качестве активаторов рецептора тромбопоэтина
TWI399368B (zh) 2004-12-14 2013-06-21 Nissan Chemical Ind Ltd Amide compounds and thrombopoietin receptor activators
TW200716580A (en) 2005-06-08 2007-05-01 Smithkline Beecham Corp (5Z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one
TWI368617B (en) 2005-07-15 2012-07-21 Nissan Chemical Ind Ltd Thiophene compounds and thrombopoietin receptor activators
JP5104752B2 (ja) 2005-07-20 2012-12-19 日産化学工業株式会社 ピラゾール化合物及びトロンボポエチンレセプター活性化剤
EP1942906A2 (en) * 2005-10-13 2008-07-16 SmithKline Beecham Corporation Methods for the preservation of platelet efficacy during storage
WO2007052808A1 (ja) 2005-11-07 2007-05-10 Nissan Chemical Industries, Ltd. ヒドラジド化合物及びトロンボポエチンレセプター活性化剤
JP5157900B2 (ja) 2006-06-07 2013-03-06 日産化学工業株式会社 含窒素ヘテロ環化合物及びトロンボポエチンレセプター活性化剤
CA2670345A1 (en) 2006-12-01 2008-06-12 Stategics, Inc. Thrombopoietin mimetics
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
JP2010525072A (ja) * 2007-04-24 2010-07-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｔｐｏ模倣薬としてのヒドロキシ−１−アゾ−誘導体の新規な製造方法
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
WO2009048953A1 (en) 2007-10-09 2009-04-16 The Trustees Of The University Of Pennsylvania Thrombopoietin receptor agonist (tpora) kills acute human myeloid leukemia cells
CN101481352A (zh) 2008-01-10 2009-07-15 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
WO2009131951A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US8207205B2 (en) 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
WO2009151862A1 (en) * 2008-05-15 2009-12-17 Smithkline Beecham Corporation Method of treatment
WO2010045310A1 (en) * 2008-10-16 2010-04-22 Glaxosmithkline Llc Method of treating thrombocytopenia
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
US7956048B2 (en) 2009-04-01 2011-06-07 Pliva Hrvatska D.O.O. Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof
US8343976B2 (en) 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
US8476249B2 (en) 2009-05-07 2013-07-02 Glaxosmithkline Llc Method of treating thrombocytopenia
EP2427053A4 (en) * 2009-05-07 2012-12-05 Glaxosmithkline Llc METHOD FOR TREATING THROMBOCYTOPENIA
US8680150B2 (en) * 2009-05-28 2014-03-25 Ligand Pharmaceuticals, Inc. Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors
JP2012528184A (ja) 2009-05-29 2012-11-12 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー トロンボポエチンアゴニスト化合物の投与の方法
CN101921232A (zh) 2009-06-11 2010-12-22 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用
MX2012006281A (es) 2009-12-01 2012-06-28 Basf Se Sistema de resina de extrusion por estirado basada en poliuretano.
CN101805291A (zh) * 2010-04-26 2010-08-18 西北大学 1-(4-异丙苯基)-3-甲基-5-吡唑啉酮及其制备方法和应用
CN103079551A (zh) 2010-09-01 2013-05-01 诺华有限公司 Hdac抑制剂与血小板减少症药物的组合
WO2012102937A2 (en) 2011-01-25 2012-08-02 Irm Llc Compounds that expand hematopoietic stem cells
WO2012121957A1 (en) * 2011-03-08 2012-09-13 Glaxosmithkline Llc Combination
WO2012121958A2 (en) * 2011-03-08 2012-09-13 Glaxosmithkline Llc Combination
US20120309796A1 (en) 2011-06-06 2012-12-06 Fariborz Firooznia Benzocycloheptene acetic acids
EP2729560A4 (en) * 2011-07-06 2014-12-03 Cellerant Therapeutics Inc MEGAKARYOCYTE PRE-PROVIDER CELLS FOR THE PRODUCTION OF BLOOD PLATES
US9981918B2 (en) * 2011-08-30 2018-05-29 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP2755955A4 (en) 2011-09-13 2015-08-19 Glenmark Generics Ltd METHOD FOR PRODUCING SUBSTITUTED 3'-HYDRAZIN BIPHENYL-3-CARBOXYLIC ACID COMPOUNDS
WO2013049605A1 (en) 2011-09-28 2013-04-04 Assia Chemical Industries Ltd. Processes for the preparation of an intermediate in the synthesis of eltrombopag
CA3173988A1 (en) 2011-10-11 2013-04-18 Dana-Farber Cancer Institute, Inc. Pyrazol-3-ones that activate pro-apoptotic bax
JP6072058B2 (ja) 2011-11-14 2017-02-01 リガンド・ファーマシューティカルズ・インコーポレイテッド 顆粒球コロニー刺激因子受容体と結合する方法および組成物
WO2013086436A1 (en) 2011-12-08 2013-06-13 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
SG11201404241SA (en) 2012-01-27 2014-08-28 Univ Montreal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
CN103360317B (zh) * 2012-04-11 2016-12-14 齐鲁制药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及用途
JP2015154715A (ja) * 2012-05-22 2015-08-27 国立大学法人旭川医科大学 ヒト単核球由来の新規血管再生細胞群及びその分化誘導法
US20140047572A1 (en) * 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
US9962370B2 (en) 2013-03-15 2018-05-08 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
EP2799425A1 (en) 2013-04-29 2014-11-05 Esteve Química, S.A. Preparation process of an agonist of the thrombopoietin receptor
WO2015029074A2 (en) 2013-09-02 2015-03-05 Hetero Research Foundation Compositions of eltrombopag
ITMI20131782A1 (it) * 2013-10-25 2015-04-26 Dipharma Francis Srl Procedimento per la preparazione di un agonista della trombopoietina
CN104628647A (zh) * 2013-11-12 2015-05-20 上海医药工业研究院 3-甲基-1-(3,4-二甲基苯基)-2-吡唑啉-5-酮的制备方法
CN104725318A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种爱曲伯帕的合成方法
WO2015111085A2 (en) 2014-01-27 2015-07-30 Cadila Healthcare Limited Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof
CN103819406B (zh) * 2014-03-17 2015-04-08 苏州明锐医药科技有限公司 艾曲波帕的制备方法
JP6762233B2 (ja) 2014-04-22 2020-09-30 ウニヴェルシテ ド モントリオールＵｎｉｖｅｒｓｉｔｅ Ｄｅ Ｍｏｎｔｒｅａｌ 化合物および造血幹細胞および／または造血前駆細胞の増大におけるその使用
CN105085276A (zh) * 2014-05-12 2015-11-25 上海医药工业研究院 艾曲波帕中间体及其制备方法和应用
CN105085287A (zh) * 2014-05-12 2015-11-25 上海医药工业研究院 3`-氨基-2`-羟基-[1,1`-联苯]-3-羧酸的制备方法
CR20170061A (es) 2014-07-17 2017-07-17 Chdi Foundation Inc Métodos y composiciones para el tratamiento de trastornos relacionados con vih
US10336706B2 (en) 2014-09-05 2019-07-02 Hetero Research Foundation Crystalline form of Eltrombopag free acid
WO2016055935A1 (en) 2014-10-06 2016-04-14 Glaxosmithkline Intellectual Property (No.2) Limited Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
WO2016068270A1 (ja) 2014-10-31 2016-05-06 日産化学工業株式会社 リガンド結合繊維及び当該繊維を用いた細胞培養基材
CN104829593B (zh) * 2015-03-26 2017-08-25 苏州福来兹检测科技有限公司 一种用于检测溶液中金属离子含量的有机化合物及其应用
WO2017042839A1 (en) 2015-09-08 2017-03-16 Actavis Group Ptc Ehf. Novel eltrombopag salt and preparation thereof
MX2018012870A (es) 2016-04-21 2019-03-28 Basf Se Metodo para la produccion de productos pultruidos a base de poliuretano.
CA3029450C (en) 2016-06-27 2021-07-13 The General Hospital Corp Dba Massachusetts General Hospital Stimulating platelet generation by activating mitochondrial biogenesis
KR20190123332A (ko) 2017-03-09 2019-10-31 바스프 에스이 복합 요소의 제조를 위한 폴리우레탄 제제
CN107021928B (zh) * 2017-04-01 2022-11-18 常州制药厂有限公司 艾曲波帕新的中间体及其制备方法和应用
EP3395331B1 (en) 2017-04-26 2019-08-21 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising eltrombopag olamine
WO2019071111A1 (en) 2017-10-06 2019-04-11 Teva Pharmaceuticals Usa, Inc. FORMS IN THE STRONG STATE OF ELTROMBOPAG CHOLINE
EP3409272B1 (en) 2018-03-07 2020-06-24 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical composition comprising eltrombopag olamine, reducing sugar, and polymeric binder
CN110467531B (zh) * 2018-05-09 2022-04-19 新发药业有限公司 一种3’-硝基-2’-羟基联苯-3-甲酸的制备方法
WO2019229572A1 (en) * 2018-06-01 2019-12-05 Aurobindo Pharma Ltd An improved process for the preparation of eltrombopag olamine and its intermediates
EP3604284B1 (en) 2018-08-02 2020-11-11 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Crystalline eltrombopag monoethanolamine salt form d
EP3604285B1 (en) 2018-08-02 2020-06-17 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Highly stable crystalline form d1 of the eltrombopag monoethanolamine salt
JP2022517211A (ja) * 2019-01-08 2022-03-07 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 二環式置換ピラゾロンアゾ誘導体の投与レジメン
EP3994126A1 (en) 2019-07-04 2022-05-11 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of key intermediates for the synthesis of eltrombopag or salt thereof
JP7083793B2 (ja) * 2019-09-10 2022-06-13 Ｊｆｅケミカル株式会社 パラターフェニルテトラカルボン酸およびパラターフェニルテトラカルボン酸二無水物の製造方法
US20210169854A1 (en) 2019-09-20 2021-06-10 Novartis Ag 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation
CN114341113A (zh) * 2019-10-21 2022-04-12 广东东阳光药业有限公司 乙酰化艾曲波帕的新晶型及其制备方法
CN114341112A (zh) * 2019-10-21 2022-04-12 广东东阳光药业有限公司 乙酰化艾曲波帕的新晶型及其制备方法
WO2021110942A1 (en) 2019-12-06 2021-06-10 Synthon B.V. Pharmaceutical composition comprising eltrombopag bis(monoethanolamine)
US20230022228A1 (en) 2019-12-06 2023-01-26 Synthon B.V. Pharmaceutical composition comprising eltrombopag bis(monoethanolamine)
TR202014694A1 (tr) 2020-09-16 2022-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Eltrombopag olami̇n i̇çeren bi̇r kati oral farmasöri̇k formülasyon
WO2022201087A1 (en) 2021-03-25 2022-09-29 Novartis Ag 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation
CN113336704B (zh) * 2021-06-11 2022-10-11 上海大学 丹参素衍生物及其制备方法和医药用途
CN114507186A (zh) * 2021-12-02 2022-05-17 天津力生制药股份有限公司 一种艾曲波帕的制备方法
WO2023111187A1 (en) 2021-12-15 2023-06-22 Galenicum Health, S.L.U Pharmaceutical compositions comprising eltrombopag

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE193350C (da)
US851444A (en) * 1905-11-13 1907-04-23 Agfa Ag Amido-oxy-sulfonic acid of phenylnaphthimidazol and process of making same.
GB779880A (en) 1953-02-27 1957-07-24 Ciba Ltd Functional derivatives of azo-dyestuffs containing sulphonic acid groups and processfor making them
US2809963A (en) * 1954-10-26 1957-10-15 Ciba Ltd Azo-dyestuffs
DE1046220B (de) * 1956-04-21 1958-12-11 Bayer Ag Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen
GB826207A (en) 1956-07-23 1959-12-31 Bayer Ag ú´-ú´-dihydroxy-monoazo dyestuffs containing pyrrolidonyl residues and their metal complex compounds
US2950273A (en) * 1956-11-20 1960-08-23 Agfa Ag Process for the production of symmetrical and unsymmetrical azo compounds
US3366619A (en) * 1965-04-09 1968-01-30 Interchem Corp Disazo pyrazolone pigments
US4435417A (en) * 1981-02-20 1984-03-06 Gruppo Lepetit S.P.A. Antiinflammatory 3H-naphtho[1,2-d]imidazoles
ES523609A0 (es) * 1982-07-05 1985-03-01 Erba Farmitalia Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos.
FR2559483B1 (fr) * 1984-02-10 1986-12-05 Sandoz Sa Composes heterocycliques contenant des groupes basiques et/ou cationiques, leur preparation et leur utilisation comme colorants
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US4880788A (en) * 1987-10-30 1989-11-14 Baylor College Of Medicine Method for preventing and treating thrombosis
US5326776A (en) * 1992-03-02 1994-07-05 Abbott Laboratories Angiotensin II receptor antagonists
IL109570A0 (en) 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
EP0638617A1 (de) 1993-08-13 1995-02-15 Ciba-Geigy Ag Pigmentsalze
DE69423661T2 (de) * 1993-12-28 2000-11-23 Dainippon Printing Co Ltd Thermische Übertragungsaufzeichnungsschicht, die einen bestimmten Farbstoff verwendet
GB2285446B (en) * 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
AU691828B2 (en) 1994-02-14 1998-05-28 University Of Washington Hematopoietic protein and materials and methods for making it
US5482546A (en) * 1994-03-30 1996-01-09 Canon Kabushiki Kaisha Dye, ink containing the same, and ink-jet recording method and instrument using the ink
US5760038A (en) 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5746821A (en) 1995-02-13 1998-05-05 Engelhard Corporation Pigment compositions
EA001220B1 (ru) 1995-06-07 2000-12-25 Глаксо Груп Лимитед Пептид или пептидомиметик, который связывается с рецептором тромбоэтина, фармацевтическая композиция и способ лечения
US5622818A (en) * 1995-11-29 1997-04-22 Eastman Kodak Company Color photographic elements containing yellow colored magenta dye forming masking couplers
US5669967A (en) * 1996-05-30 1997-09-23 Engelhard Corporation Pigment compositions
US5932546A (en) * 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
GB9715830D0 (en) 1997-07-25 1997-10-01 Basf Ag Reactive dyes containing piperazine
WO1999011262A1 (en) 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
CA2308317A1 (en) * 1997-10-31 1999-05-14 Smithkline Beecham Corporation Novel metal complexes
DE19851389A1 (de) * 1998-11-07 2000-05-11 Dystar Textilfarben Gmbh & Co Gelbe Farbstoffmischungen von wasserlöslichen faserreaktiven Azofarbstoffen und ihre Verwendung
GC0000177A (en) * 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
US6750342B1 (en) * 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
AU6023300A (en) * 1999-07-26 2001-02-13 Shionogi & Co., Ltd. Drug compositions exhibiting thrombopoietin agonism
DE60025632T2 (de) * 1999-09-10 2006-08-10 Smithkline Beecham Corp. Thrombopoietin-mimetika
WO2001021180A1 (en) * 1999-09-24 2001-03-29 Smithkline Beecham Corporation Thrombopoietin mimetics
EP1228051A1 (en) 1999-11-05 2002-08-07 SmithKline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics
ES2160560T1 (es) 1999-11-10 2001-11-16 Curacyte Ag Colorantes o,o'-dihidroxi-azoicos como constituyentes de medicamentos para el tratamiento de trombopenias.
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
MY133845A (en) * 2000-03-10 2007-11-30 Smithkline Beecham Corp Il-8 receptor antagonists
US6436915B1 (en) 2000-04-07 2002-08-20 Kinetek Pharmaceuticals, Inc. Pyrazole compounds
US6214813B1 (en) * 2000-04-07 2001-04-10 Kinetek Pharmaceuticals, Inc. Pyrazole compounds
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
US6642265B1 (en) * 2000-09-08 2003-11-04 Smithkline Beecham Corporation Thrombopoietin mimetics
US7241783B2 (en) 2000-12-19 2007-07-10 Smithkline Beecham Corporation Thrombopoietin mimetics
AU2002241734B2 (en) 2000-12-21 2006-02-23 Ligand Pharmaceuticals Regulated activation of cell-membrane receptors by metal-chelating agonists
EP1361220A4 (en) 2001-01-26 2005-09-07 Shionogi & Co CYCLIC COMPOUNDS WITH THROMBOPOIETIN RECEPTAGONISM
CA2435143A1 (en) 2001-01-26 2002-08-01 Shionogi & Co., Ltd. Halogen compounds having thrombopoietin receptor agonism
EP1370252A4 (en) 2001-03-01 2006-04-05 Smithkline Beecham Corp Thrombopoietin mimetics
JP3927001B2 (ja) 2001-06-15 2007-06-06 三菱化学株式会社 色素セット、インクセット並びに記録方法
US6560161B1 (en) * 2001-08-30 2003-05-06 Micron Technology, Inc. Synchronous flash memory command sequence
MXPA04005204A (es) 2001-11-30 2005-11-04 Quadra Logic Tech Inc Derivados de hidrazonipirazol y su uso como terpapeuticos.
AU2003213673A1 (en) 2002-03-01 2003-09-16 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
TWI280128B (en) 2002-05-22 2007-05-01 Smithkline Beecham Corp 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US7414040B2 (en) * 2002-06-06 2008-08-19 Smithkline Beecham Corporation Thrombopoietin mimetics
TWI324593B (en) * 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
AU2003297925A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Thrombopoietin mimetics
EP2387998A1 (en) 2003-04-29 2011-11-23 Glaxosmithkline LLC Methods for treating degenerative diseases/injuries
US20090298179A1 (en) * 2003-04-29 2009-12-03 Connie Erickson-Miller Methods For Treating Degenerative Diseases/Injuries
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
MX2007004765A (es) * 2004-10-25 2007-07-09 Ligand Pharm Inc Compuestos y metodos que modulan la actividad de la trombopoyetina.
EP1942906A2 (en) * 2005-10-13 2008-07-16 SmithKline Beecham Corporation Methods for the preservation of platelet efficacy during storage
CA2670345A1 (en) * 2006-12-01 2008-06-12 Stategics, Inc. Thrombopoietin mimetics

Also Published As

Publication number Publication date
HUP0302257A2 (hu) 2003-10-28
WO2001089457A2 (en) 2001-11-29
ATE445606T1 (de) 2009-10-15
IL152988A0 (en) 2003-06-24
PL393259A1 (pl) 2011-07-04
PL359270A1 (en) 2004-08-23
EP1294378A4 (en) 2004-01-28
HK1117825A1 (en) 2009-01-23
AU7493801A (en) 2001-12-03
NO2010017I1 (no) 2010-09-20
US7648971B2 (en) 2010-01-19
CN101343251B (zh) 2011-11-09
CN101343251A (zh) 2009-01-14
WO2001089457A3 (en) 2002-03-07
HK1056114A1 (zh) 2004-02-06
IL193618A0 (en) 2009-02-11
DE60130760D1 (de) 2007-11-15
SI1889838T1 (sl) 2010-02-26
NZ522474A (en) 2004-10-29
KR20070087255A (ko) 2007-08-27
CA2411468C (en) 2008-04-15
BR0111116A (pt) 2003-04-08
DE60130760T2 (de) 2008-07-17
US20090155203A1 (en) 2009-06-18
CY2010012I2 (el) 2020-05-29
PT1889838E (pt) 2010-01-19
TWI305207B (en) 2009-01-11
ES2328179T3 (es) 2009-11-10
CY1109730T1 (el) 2014-09-10
NO2010017I2 (no) 2012-06-11
EP1294378B1 (en) 2007-10-03
BRPI0111116B8 (pt) 2021-05-25
US7332481B2 (en) 2008-02-19
JP4546919B2 (ja) 2010-09-22
CZ303176B6 (cs) 2012-05-16
DE60140224D1 (de) 2009-11-26
CY2010012I1 (el) 2012-01-25
US7790704B2 (en) 2010-09-07
BE2010C018I2 (da) 2020-08-20
EP1889838A1 (en) 2008-02-20
CY1107087T1 (el) 2012-01-25
NO2020040I1 (no) 2020-11-19
US7160870B2 (en) 2007-01-09
FR10C0034I2 (fr) 2011-04-29
CN101343250A (zh) 2009-01-14
IL193619A0 (en) 2009-02-11
HU0800310D0 (en) 2008-07-28
CN1444477A (zh) 2003-09-24
DK1889838T3 (da) 2010-02-08
US20080090996A1 (en) 2008-04-17
CN100423721C (zh) 2008-10-08
EP1889838B1 (en) 2009-10-14
NO20025566D0 (no) 2002-11-20
HU227476B1 (en) 2011-07-28
CZ20023852A3 (cs) 2003-05-14
CN101342169A (zh) 2009-01-14
CA2411468A1 (en) 2001-11-29
DE122010000037I1 (de) 2011-01-27
US7335649B2 (en) 2008-02-26
HU230387B1 (hu) 2016-03-29
US20070129338A1 (en) 2007-06-07
AU2001274938B2 (en) 2006-01-19
FR10C0034I1 (da) 2010-06-08
EP1864981A1 (en) 2007-12-12
US20090176973A1 (en) 2009-07-09
IL193617A0 (en) 2009-02-11
KR100798568B1 (ko) 2008-01-28
DE60139354D1 (de) 2009-09-03
HK1055561A1 (en) 2004-01-16
SI1294378T1 (sl) 2008-02-29
LU91681I9 (da) 2019-01-03
BR0111116B1 (pt) 2013-10-08
IL193617A (en) 2013-06-27
US7674887B2 (en) 2010-03-09
MY136707A (en) 2008-11-28
IL152988A (en) 2009-02-11
PL218617B1 (pl) 2015-01-30
NO20025566L (no) 2003-01-22
EP1294378A2 (en) 2003-03-26
HK1113057A1 (en) 2008-09-19
ES2294000T3 (es) 2008-04-01
SI1864981T1 (sl) 2009-12-31
AR030696A1 (es) 2003-09-03
JP2006137764A (ja) 2006-06-01
US7452874B2 (en) 2008-11-18
LU91681I2 (fr) 2010-06-21
MXPA02011621A (es) 2004-05-17
US20040019190A1 (en) 2004-01-29
ES2334843T3 (es) 2010-03-16
KR20030060773A (ko) 2003-07-16
JP2003534257A (ja) 2003-11-18
PT1294378E (pt) 2008-01-09
EP1864981B1 (en) 2009-07-22
NZ533308A (en) 2005-10-28
DK1864981T3 (da) 2009-09-07
CY1109435T1 (el) 2014-08-13
AU2001274938C1 (en) 2006-09-28
AR066036A2 (es) 2009-07-22
US7439342B2 (en) 2008-10-21
PL216528B1 (pl) 2014-04-30
HUP0800710A2 (hu) 2003-10-28
CN101343250B (zh) 2011-09-21
HU230487B1 (hu) 2016-08-29
NO324246B1 (no) 2007-09-17
HUP0302257A3 (en) 2007-03-28
US7473686B2 (en) 2009-01-06
ATE374772T1 (de) 2007-10-15
JP3813875B2 (ja) 2006-08-23
US20090176746A1 (en) 2009-07-09
EP1864981B8 (en) 2009-11-11
HU0800710D0 (en) 2009-01-28
US20070179192A1 (en) 2007-08-02
KR100847172B1 (ko) 2008-07-17
US20080214640A1 (en) 2008-09-04
PT1864981E (pt) 2009-08-31
US20080090787A1 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
DK1294378T3 (da) Trombopoietin-mimetika
DE50105915D1 (de) Schutzhülle
ATE290000T1 (de) Muscarinagonisten
ATE252099T1 (de) Biarylcarboxamide
DZ3409A1 (fr) Association therapeuthique
ATE312098T1 (de) Thiazinoxazolidinon
NO20030447D0 (no) Brönnkontroll
ATA2932001A (de) Schneefräse
ATE262530T1 (de) Indolochinazolinone
ATE298751T1 (de) 7-oxopyridoryrimidine
DE1274523T1 (de) Hochdruckumformspülanlage
DE60133560D1 (de) Kohlenstofffaserprecursorbündel
AR028336A1 (es) 4-hidroxi-tetrahidropiridonas fenilsubstituidas
ATE509008T1 (de) Sulfonylguanidine
AR028061A1 (es) 2-enamino-cetonitrilos fenil-substituidos
AR027931A1 (es) Antitranspirantes
ATE476423T1 (de) Benzoylpyridazine
DE10052925B4 (de) Schaukelbett
AR027982A1 (es) Aril- y heteroarilsulfonatos
NO20011665D0 (no) Aviksboringssystem
ATE284887T1 (de) Thienopyrrolidinone
ATA7092001A (de) Skibindungseinstellgerät
AT500246B8 (de) Chokerring
ES1045827Y (es) Jamonero
ATA19392000A (de) Kippflügelflugzeug